Matthew

Matthew's journal language has shifted from active to passive voice over the past 6 weeks. February entries used agentive constructions ("I decided", "I want to", "I'm going to"); May entries lean on receptive/depleted forms ("nothing matters", "I'm just tired", "what's the point"). This is consistent with the affect-action coupling literature on depressive cognition.

The April 18 inflection doesn't appear in his self-report — he hasn't named a precipitant. But across his data: a calendar event "Mom call: Dad's MRI" appears two days prior; voice journal mentions of family rise 4× that week and then drop entirely. Worth gently probing in session.

• Behavioral activation candidates from his past data: drawing (Procreate, last active March 31), running (Strava, last active April 18 — same date), Sunday calls with mother.
• Sleep–mood coupling is r = 0.71 in his data. Late-night journaling (11 entries post-midnight) is both a symptom and a maintaining factor. Worth pairing CBT-I with the depression work.
• Therapeutic alliance is intact — Matthew has attended every session and rates them 8.5+/10 in post-session check-ins. Medication adherence has held at 93%. He is participating in care; the system is what's slipping.

Matthew's nutrition pattern is secondary to his mood shift, not a primary disorder, but it's now reinforcing it. He isn't dieting or restricting deliberately — he's forgetting and skipping. The behavioral signature is unmistakable:

• Meal planning infrastructure abandoned April 18. Both NYT Cooking and Paprika went silent on the same date. The mental energy for "what am I going to eat" is gone.
• Convenience apps have absorbed the gap. DoorDash up 380%, Uber Eats up 240%. Average order time clusters 9 PM – 12 AM — he eats once a day, late, fast.
• Protein is the most actionable gap. ~60g/day estimated. Delivery patterns lean carb-heavy (Thai, pasta, pizza). Low protein is itself a fatigue-and-mood amplifier — a feedback loop.
• Caffeine has replaced food as energy source. 4.6 cups/day, last cup median 4:42 PM. This degrades sleep, which degrades mood, which degrades appetite — closing the loop.
• Unintentional weight loss (4 lb / 2.8% over 5 weeks) meets DSM-5 MDD Criterion A3 threshold. Worth flagging on the medical side.

Practical wins for a first session: protein-forward grab-and-go breakfast (no cooking required), reinstate one app reminder, move caffeine cutoff to noon, schedule one shared cooked meal/week with partner. Don't lead with meal planning — his executive bandwidth can't carry it right now.

Matthew's last app interaction averages 2:48 AM. The 30 minutes before sleep onset are dominated by high-stimulation short-form video. Two specific findings worth raising in care planning:

• Pickups-in-bed: avg 22 per night between getting into bed and falling asleep (motion-data-confirmed).
• Wake-and-scroll: in 9 of the past 14 nights, Matthew woke between 3–5 AM, opened his phone, and stayed on it 20+ minutes before returning to sleep. This is a high-yield CBT-I intervention target.

The pattern looks like secondary insomnia + delayed sleep phase coupled to depressive features:

• Late bedtime, delayed onset, fragmented mid-sleep, normal-to-slightly-early morning wake.
• Pre-existing baseline (Aug 2023 – Mar 2026) was healthy: 7h, low latency, 1.1 wake events.
• Coupling to mood is tight (r = 0.71). CBT-I likely high-yield, but standalone CBT-I without treating the mood substrate will under-perform.

Highest-leverage targets: charge phone outside bedroom, caffeine cutoff at noon, fixed wake time (not bedtime), bright light exposure 7–9 AM. Sertraline timing review with prescriber if AM activation overlaps with daytime fatigue.

The activity drop is sharper than mood-related withdrawal alone would predict. Two findings worth attention:

• Walking speed has declined 18% (from 3.4 mph to 2.8 mph), independent of step count. Speed is a fairer measure than count here — it reflects gait effort, not just opportunity.
• Stairs avoided: elevator-vs-stairs ratio flipped from 30/70 to 92/8 in the office building over the same period.

Both metrics return when he has a "good day" mood log — suggesting state-dependent psychomotor slowing rather than fixed deconditioning. Worth a brief functional check in-session.

The +9 BPM resting HR and ~38% HRV reduction are characteristic of sustained sympathetic dominance, consistent with depressive-anxious states. No findings suggesting primary cardiac pathology in the passive data (no ectopy patterns, no high-HR events, no oxygen desaturation overnight).

Worth noting for medication review: Sertraline is generally HR-neutral, but check whether dose change or other meds have changed. If clinical picture warrants, a 12-lead and basic labs would rule out thyroid or anemia overlay.

Matthew has been on Sertraline 100mg for 21 months with documented prior response. Current presentation suggests either breakthrough symptoms, dose-relative subtherapeutic response, or a precipitant-driven episode despite ongoing treatment. Adherence remains strong (93%) — this is not a non-compliance picture.

Options ranked in the Treatment Plan panel. Briefly: (A) dose-increase Sertraline 100→150mg is first-line and likely sufficient; (B) bupropion augmentation is contraindicated by prior adverse response; (C) venlafaxine class-switch is reserve; (D) aripiprazole augmentation is premature; (E) treating the medical layer (Vit D, ferritin, repeat TSH) should run in parallel. PGx testing now becomes reasonable if Option A doesn't produce response at 8 weeks.

Mobility metrics have declined in proportion with overall energy. The pattern is bilateral, symmetric, and reverses on good-mood days — strongly consistent with depressive psychomotor slowing rather than physical pathology. No fall risk indicators. No need for PT referral unless decline persists post-mood-recovery.

2.8% body-weight loss over 5 weeks is not severe in isolation but is clinically meaningful in context:

• It is unintentional (no diet, no GLP-1, no procedure).
• Trajectory matches reduced intake (~530 kcal/day deficit) — the math checks out.
• It meets DSM-5 MDD Criterion A3 ("significant unintentional weight loss").
• Continued at this rate, would total ~5% loss by next monthly visit — worth a weigh-in.

Address by treating the upstream nutrition/mood pattern; rule out medical contributors if loss continues past behavioral intervention window.

The +340% discretionary spend by itself looks like it could be a hypomanic-spectrum signal. It isn't. The full pattern argues against bipolar:

• No paired energy elevation. Hypomanic spending typically co-occurs with reduced sleep need, elevated activity, and goal-directed pursuit. Matthew's sleep is reduced with fatigue, his steps are down 71%, and his goal-pursuit is collapsed. Activity and spending are decoupled — not the bipolar signature.
• Purchase content is consumption-oriented, not ambition-oriented. Hypomanic spending often clusters around projects, plans, expansion (business courses, large items, travel). Matthew's purchases are passive: streaming, doomscrolling-adjacent retail, instant gratification.
• Late-night timing aligns with insomnia, not energy. The 11 PM – 3 AM cluster overlaps the doom-scroll window. This is "I can't sleep so I scroll-and-buy", not "my mind is racing and I'm building things."
• Return rate (16%) is high. Buyer's-regret pattern, consistent with impulse-with-low-conviction. Hypomanic purchases tend to feel justified in the moment and later.
• 14-month longitudinal data shows no prior hypomanic episodes. No previous spending spikes, no energy elevations, no decreased-sleep-with-mood-elevation patterns.

MDQ would likely score low. Bipolar differential should remain considered but unsupported by passive data. If Matthew endorses any past energy/spending pairings on direct interview, revisit.

The spending is doing emotional work for him. Three distinct sub-patterns:

• Numbing (entertainment, streaming subscriptions, in-app purchases): purchased when distress is acute · cluster around 11 PM – 1 AM · doesn't require physical presence · low engagement threshold.
• Replacement-for-effort (food delivery, mobile coffee orders): substitutes for activities he used to do herself (cook, walk to coffee) · executive-function-conserving · also functions as caretaking-from-outside when he can't caretake herself.
• Pseudo-control (Amazon impulse buys, returned items): buying gives a moment of agency-feeling that his broader life isn't providing · the act of buying matters more than the items · 16% return rate suggests the goods themselves aren't the point.

Worth gently surfacing in session — without shame. Matthew is using money the way another patient might use food, alcohol, or work. Frame it as a coping tool that has worked enough to keep doing, not as a failure. Healthier substitutes (calling a friend, a 10-minute walk) need to be at least as accessible as the phone in his hand.

Critically, Matthew's baseline financial stability is not threatened. Income is stable (W-2 paychecks deposited on time, no reduced hours), savings continues to accumulate, no debt acceleration. He has ~$84 in monthly slip from late fees + drift + subscription creep — annoying, not catastrophic.

The actionable interventions are protective, not restrictive:

• Audit + cancel the 3 forgotten trials and pause Equinox until Matthew is using it again. ~$212/mo recovered with minimal effort.
• Late-night purchase pause — most cards support a "24-hour cooling" or app-level spending limit. Reduces post-11 PM purchases without removing access.
• Auto-pay every bill — eliminate the executive-function load of paying bills manually when his bandwidth is low. Eliminates late fees entirely.
• Don't touch the emergency fund auto-transfer — it's working without his attention, which is the design.

Financial intervention here is protective infrastructure, not behavior change. The behavior will follow when the mood recovers.

Audio levels themselves are safe. The behavioral signal is the 8.4hr/day exposure — up 4.7× from baseline. This often co-occurs with social withdrawal (audio in = world out). Worth surfacing gently, not as a hearing concern but as a coping-shape question.

All respiratory metrics within normal range. No evidence of sleep-disordered breathing contributing to Matthew's poor sleep quality — the sleep issue is behavioral and mood-driven, not respiratory.

Three findings shift the differential meaningfully and warrant team-wide awareness:

• Subclinical hypothyroidism (TSH 4.8, free T4 normal). This is a known depression mimic — fatigue, weight changes, low mood. The mood picture may have a meaningful endocrine layer worth treating in parallel with psychiatric care. Recommend re-check TSH + free T4 in 6 weeks. If TSH rises further or T4 drops, initiate low-dose levothyroxine in coordination with Dr. Almeida (psychiatry).
• Vitamin D deficiency (18 ng/mL). Strongly associated with depressive symptoms in observational studies; replacement is low-risk and high-value. Initiate D3 5,000 IU daily × 8 weeks then re-check.
• Low-normal ferritin (22). Iron deficiency without anemia can contribute to fatigue and cognitive symptoms. In a 34M without menstrual loss, this finding warrants a dietary and GI consideration — workup if persistent. Recommend oral iron supplementation with monitoring; re-check ferritin in 12 weeks; consider basic GI evaluation if doesn't improve.

Critically: these findings do not rule out psychiatric framing — they add a treatable medical layer that may have been amplifying psychiatric symptoms. The wrong move is to either (a) attribute everything to thyroid and stop psychiatric care, or (b) ignore the labs and treat psychiatrically alone. Both modalities indicated.

• Sulfa allergy rules out certain antibiotic classes (Bactrim) but does not contraindicate sulfa-containing drugs without an aromatic amine group (most modern psychiatric medications are safe).
• Penicillin allergy rules out beta-lactams unless evaluated by allergist for graded challenge.
• Tree nut allergy requires checking excipients in any new medication — some capsule formulations and certain compounded medications can contain tree nut oils. System auto-flags this on every Rx review.
• No psychiatric medication allergies on record — Sertraline, prior SSRIs, and bupropion previously tolerated without allergic reaction (separate from side effect tolerability).
• Cetirizine PRN seasonal use noted — no interaction concerns with current Rx; mild anticholinergic effect with chronic use worth noting.